Last updated on February 2020

Haplo-SCT vs ASCT With or Without Decitabine in AML CR1

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute myeloid leukemia | Acute Myelogenous Leukemia (AML)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Age >= 18y
  • Diagnosed as AML (except acute promyelocytic leukemia M3) for the first time
  • Minimal Residual Disease (MRD) test can be achieved (molecular biology first if applicatable, and/or cytogenetics and/or immunophenotyping)
  • Presence of an available haplo-mismatch related donor

Exclusion Criteria:

  • Contra-indications of chemotherapy or hematopoietic stem cell transplantation
  • Presence of an available identical sibling donor or a 10/10 HLA loci-matched unrelated donor
  • Participating in other clinical trials concerning the prophylaxis of disease recurrence after ASCT
  • No effective contraception
  • Pregnant or lactating females
  • Other causes which are not suitable for the trial in investigator's consideration

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.